Investissement Quebec
VC Fund
Quebec, Canada
Investissement Quebec is a VC fund in Quebec focused on Manufacturing and Software. Investissement Québec offers a range of financing solutions to SMEs and large companies. Investissement Québec partners in consulting and financing to support their client's expansion project in Québec. They offer the combined advantages of financial institutions and economic development agencies.
- Total investments:
- 262
- Last investment:
- Lead investor:
- 34%
Last updated:
For AI agents: llms.txt
Industries Investissement Quebec invests in
Stages Investissement Quebec invests in
Countries Investissement Quebec invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Didier Leconte
|
|||
Alex Laverdière
|
|||
Benoit Girard
|
|||
Bicha Ngo
|
|||
Edouard T. Blais
|
|||
| See all 8 contacts → | |||
Investment Focus
Industry
- Manufacturing 24 (9%)
- Software 23 (9%)
- Health Care 23 (9%)
- Information Technology 18 (7%)
- Artificial Intelligence 15 (6%)
Stage
- Seed 33 (13%)
- Funding Round 30 (11%)
- Debt Financing 22 (8%)
- Series A 21 (8%)
- Series B 21 (8%)
Country
- Canada 141 (54%)
- Spain 1 (0%)
- France 1 (0%)
- United States 1 (0%)
- United Kingdom 1 (0%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Didier Leconte
Vice-président, Sciences de la vie et technologie | Vice President, Life Sciences & Technology
|
Vice-président, Sciences de la vie et technologie | Vice President, Life Sciences & Technology | Total investments: 2 | Find email | |
|
Alex Laverdière
Vice President
|
Vice President | Total investments: 3 | Find email | |
|
Benoit Girard
Senior Director - Venture Capital, Innovation and Impact Investment
|
Senior Director - Venture Capital, Innovation and Impact Investment | Total investments: 0 | Find email | |
|
Bicha Ngo
CEO
|
CEO | Total investments: 33 | Find email | |
|
Edouard T. Blais
Senior Advisor, Investment, Venture Capital
|
Senior Advisor, Investment, Venture Capital | Total investments: 0 | Find email | |
| See all 8 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Altex
|
Altex serves in the field of window treatments, recognized worldwide. Their products are roller shades, ambio roller shades, day and night roller shades, sky light liners, multiform fixed shades, exterior blinds, and motorized drapery tracks. | $3.6M / Debt Financing / Aug 05, 2026 | |
Kruger Inc
|
Kruger Inc. is active in traditional industry sectors as pulp and paper, forest products, and containerboard and packaging. Kruger Inc. is now also a major player in renewable energy, tissue products, wines and spirits, and recycling. | $51.2M / Debt Financing / May 11, 2026 | |
|
Kruger Pulp and Paper Limited Partnership
|
Kruger Pulp and Paper Limited Partnership is a holding company affiliated with the Kruger Inc. group, focused on pulp and paper manufacturing and related industrial operations. | $18.3M / Debt Financing / May 11, 2026 | |
|
Kruger Pulp and Paper Limited Partnership
|
Kruger Pulp and Paper Limited Partnership is a holding company affiliated with the Kruger Inc. group, focused on pulp and paper manufacturing and related industrial operations. | $3.7M / Private Equity / May 11, 2026 | |
Aplantex
|
Aplantex produces plant-based active compounds for application in the pharma, cosmetics, and agri-food industries. | $3.7M / Convertible Note / May 07, 2026 | |
CELYSTRA Pharma
|
CELYSTRA Pharma is a biopharmaceutical company that identifies and acquires innovative therapies developed internationally and brings them to Canada. The company focuses on making treatments available to patients with rare and specialized diseases who face unmet medical needs. CELYSTRA Pharma licenses and commercializes therapies, working tofacilitate access to medicines that address gaps in current treatment options. It collaborates with international partners to introduce these products into the Canadian healthcare system. The company begins its activities with a Health Canada–approved treatment for familial chylomicronemia syndrome, a rare genetic disorder. CELYSTRA Pharma concentrates on underserved patient populations and structured market access for novel therapies. | $14.7M / Seed / May 05, 2026 | |
Opalia
|
Opalia develops food technology focused on producing animal-free dairy using cell-based systems. It creates real milk by cultivating mammary cells in controlled bioreactors, generating proteins, fats, and sugars that match conventional dairy composition. The company provides a platform that produces complete milk rather than isolated ingredients,allowing direct use in products such as cheese, butter, and ice cream. Its offering is structured as a business-to-business model, supplying milk and dairy inputs to food manufacturers and partners for integration into existing production processes.Opalia also develops modular bioreactor systems and production methods designed to scale manufacturing of cell-based dairy. The technology is applied to support food production systems that operate without livestock while maintaining functional properties of traditional dairy. | $2.3M / Seed / Apr 28, 2026 | |
|
Opalia
|
Opalia develops food technology focused on producing animal-free dairy using cell-based systems. It creates real milk by cultivating mammary cells in controlled bioreactors, generating proteins, fats, and sugars that match conventional dairy composition. The company provides a platform that produces complete milk rather than isolated ingredients,allowing direct use in products such as cheese, butter, and ice cream. Its offering is structured as a business-to-business model, supplying milk and dairy inputs to food manufacturers and partners for integration into existing production processes.Opalia also develops modular bioreactor systems and production methods designed to scale manufacturing of cell-based dairy. The technology is applied to support food production systems that operate without livestock while maintaining functional properties of traditional dairy. | $2.3M / Seed / Apr 28, 2026 | |
SB Quantum
|
SBQuantum is building an integrated product offering that first detects and then understands changes in magnetic resonance lines before visualizing the output on a customizable platform. They use magnetic intelligence to build a precise, localized magnetic model of the earth that will allow them to understand and navigate through the environment. | $4M / Seed / Apr 16, 2026 | |
Nouveau Monde Graphite
|
Nouveau Monde is developing its operations with the highest environmental standards in one of the most advanced mining friendly jurisdictions in the world in Québec, Canada; they’re targeting the growing North-American lithium-ion battery market. Local, green, and safe supply of natural graphite produced with a low environmental footprint is,according to us, of added value to the North-American lithium-ion battery manufacturers. | $309.5M / Post-IPO Equity / Apr 09, 2026 | |
| See all 262 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does Investissement Quebec invest in?
Investissement Quebec invests primarily in Manufacturing, Software and Health Care startups, most often at Seed and Funding Round stage. Most of the 262 investments tracked by Shizune back companies in Canada. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Investissement Quebec?
Public channels for Investissement Quebec include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Investissement Quebec?
The team at Investissement Quebec includes Didier Leconte (Vice-président, Sciences de la vie et technologie | Vice President, Life Sciences & Technology), Alex Laverdière (Vice President) and Benoit Girard (Senior Director - Venture Capital, Innovation and Impact Investment), among 8 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
